Patients also experienced significant weight loss and improvements in metabolic parameters
The decrease was not of enough magnitude to have significantly less patients below risk cutoff values (0.24 for AIP, 36 for HSI), although the proportion of those who achieved this goal was higher in the non-CKD group ( Supplementary Figures 2A, C )
Retatrutide treats obesity a serious condition but FDA-approved obesity medications already exist: Wegovy (semaglutide) and Zepbound (tirzepatide)
This, in turn, can help to reduce muscle fatigue and enhance muscle performance
Prevention and Treatment of Metabolic Syndrome
Compounded GLP-1 options bypass these insurance barriers entirely, allowing patients to start therapy within days rather than weeks or months, which has contributed substantially to direct-to-consumer adoption rates